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We examined the distribution of single nucleotide polymorphisms (SNPs) in 
 
nitric oxide 
synthase 2A
 
, 
 
monocyte chemoattractant protein–1
 
 (
 
MCP-1
 
), 
 
regulated on activation
 
,
 
 normal 
T cell expressed and secreted
 
, and 
 
macrophage inflammatory protein–1
 
 
 
 
 
genes in 
tuberculosis patients and healthy controls from Mexico. The odds of developing tuberculosis 
were 2.3- and 5.4-fold higher in carriers of 
 
MCP-1
 
 genotypes 
 
AG
 
 and 
 
GG 
 
than in 
homozygous 
 
AA
 
. Cases of homozygous 
 
GG
 
 had the highest plasma levels of MCP-1 and the 
lowest plasma levels of IL-12p40, and these values were negatively correlated. Furthermore, 
stimulation of monocytes from healthy carriers of the genotype 
 
GG
 
 with 
 
Mycobacterium 
tuberculosis
 
 antigens yielded higher MCP-1 and lower IL-12p40 concentrations than parallel 
experiments with monocytes from homozygous 
 
AA
 
. Addition of anti–MCP-1 increased IL-
12p40 levels in cultures of 
 
M. tuberculosis
 
–stimulated monocytes from homozygous 
 
GG
 
, and 
addition of exogenous MCP-1 reduced IL-12p40 production by 
 
M. tuberculosis
 
–stimulated 
monocytes from homozygous 
 
AA
 
. Furthermore, we could replicate our results in Korean 
subjects, in whom the odds of developing tuberculosis were 2.8- and 6.9-fold higher in 
carriers of 
 
MCP-1
 
 genotypes 
 
AG
 
 and 
 
GG
 
 than in homozygous 
 
AA
 
. Our findings suggest that 
persons bearing the 
 
MCP-1
 
 genotype 
 
GG
 
 produce high concentrations of MCP-1, which 
inhibits production of IL-12p40 in response to 
 
M. tuberculosis
 
 and increases the likelihood 
that 
 
M. tuberculosis
 
 infection will progress to active pulmonary tuberculosis.
 
Studies of monozygotic and dizygotic twins
have demonstrated that genetic factors con-
tribute considerably to the development of
tuberculosis (1, 2). The 17q11.2 chromosomal
region has been linked to susceptibility to tu-
berculosis (3, 4) and includes genes encoding
for several chemokines that may contribute to
immunity against tuberculosis. One gene en-
codes 
 
monocyte chemoattractant protein–1 
 
(
 
MCP-1
 
),
a chemoattractant for monocytes and T lym-
phocytes, which are central components of the
granulomatous response (5). Other 
 
 
 
 chemo-
kine genes in this region are 
 
macrophage in-
flammatory protein–1
 
 
 
 
 
(
 
MIP-1
 
 
 
), and 
 
regulated
on activation, normal T cell expressed and secreted
 
(
 
RANTES
 
), which are involved in recruitment
of T cells to inflammatory sites (6), activation of
T cells (7), and inhibition of intracellular
growth of 
 
Mycobacterium tuberculosis
 
 (8). Another
interesting gene in this region is the 
 
nitric oxide
synthase 2A 
 
(
 
NOS2A
 
) gene, which generates
nitric oxide, a molecule with antimicrobial
activity against 
 
M. tuberculosis
 
 (9).
Single nucleotide polymorphisms (SNPs)
in the 
 
MCP-1
 
 and 
 
NOS2A
 
 promoters influ-
ence expression of these genes (10, 11), and
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SNPs in the 
 
RANTES
 
 and 
 
MIP-1
 
 
 
 genes are associated
with susceptibility to HIV infection (12). We therefore per-
formed a study to determine whether susceptibility to devel-
opment of tuberculosis after infection was associated with
any of these four SNPs and to delineate the mechanisms un-
derlying this susceptibility.
 
RESULTS
Features of clinical and genomic controls
 
We recruited 445 new sputum smear–positive cases with
culture-confirmed tuberculosis and 518 healthy controls in
Mexico. All cases and controls were recruited through the
World Health Organization’s Mexican DOTS program for
early detection of new tuberculosis cases (13), in which
 
 
 
95% of cases are newly diagnosed and only 5% are cases of
tuberculosis relapses (13).
Genotyping was successful in 98% of tuberculosis pa-
tients and healthy controls. Mexican controls were stratified
into 334 healthy tuberculin reactors and 176 tuberculin-neg-
ative persons. The three groups were similar in demograph-
ics, body mass index ([BMI] before development of disease
in the case of tuberculosis patients), household incomes, and
consumption of cigarettes and alcohol (Table I). The ab-
sence of heavy cigarette or alcohol use was probably because
of the exclusion of persons with diseases associated with
these habits.
Chest radiographs showed alveolar infiltrates in all 435
tuberculosis patients, and hilar adenopathy was present in
417 (96%) cases from Mexico. No patients had a history of
tuberculosis or previous treatment for tuberculosis. They
were in contact with an individual with active tuberculosis
for a period of no more than 8 mo before the symptoms
were evident. None of them had other medical conditions
affecting immunity. These clinical and epidemiological find-
ings are consistent with the fact that our Mexican patients
are new tuberculosis cases.
Mexican Mestizos from Mexico D.F. (the Federal Dis-
trict) have an admixture of Spanish (50.03 
 
 
 
 4.11%), Amer-
indian (49.03 
 
 
 
 3.76%), and African (0.94 
 
 
 
 1.27%) traits
(14). Thus, to determine whether our cases and controls
were homogeneous in terms of admixture we genotyped 30
unlinked SNPs as genomic controls (15, 16). These SNP
were not associated with disease and all of them were in
Hardy-Weinberg equilibrium (Table S1, available at http://
www.jem.org/cgi/content/full/jem.20050126/DC1).
Thus, our demographic and genomic control data indi-
cate that it is unlikely that our results are caused by selection
or information bias (including genotyping errors) (17), an
unadjusted known confounder, or population stratification.
To confirm our findings in Mexicans in an ethnically dis-
tinct population, we studied subjects from Korea, including
129 with tuberculosis and 162 healthy controls. Demo-
graphic information of this sample is provided in Table S2
(available at http://www.jem.org/cgi/content/full/jem.
20050126/DC1). There were no important differences in
age, gender distribution, or BMI between cases and controls
(Table S2).
 
The –2518 
 
MCP-1
 
 promoter polymorphism is associated 
with susceptibility to pulmonary tuberculosis
 
In Mexican control subjects, genotypes at the four selected
loci tested in the 17q11.2 chromosomal region were in
Hardy-Weinberg equilibrium. None of the 
 
NOS2A
 
,
 
RANTES
 
, and 
 
MIP-1
 
 
 
 alleles (Table II) or genotypes (un-
published data) were associated with tuberculosis. In con-
trast, allele 
 
G
 
 of the 
 
MCP-1
 
 gene was strongly associated
with tuberculosis compared with healthy tuberculin reactors,
with a significant 
 
 
 
2
 
 of 12.9 (P 
 
 
 
 0.0003), as corrected for
population stratification/admixture (divided by 
 
 
 
 
 
 
 
 1.332)
and for the number of comparisons, and an odds ratio (OR)
of 2.43 (95% confidence interval [CI] 
 
 
 
 1.96–3.02). Similar
results were obtained by comparing tuberculosis patients
with healthy tuberculin-negative persons (corrected 
 
 
 
2
 
 
 
 
 
9.08; P 
 
 
 
 0.0026; OR 
 
 
 
 2.45; 95% CI 
 
 
 
 1.88–3.19; Tables
II and III). Carriers of 
 
MCP-1
 
 genotypes 
 
AG
 
 and 
 
GG
 
 were
significantly overrepresented among tuberculosis cases com-
pared with healthy tuberculin reactors and tuberculin-nega-
tive controls (Table II). A trend test was also significant (P 
 
 
 
0.00001 for both comparisons), indicating that the 
 
MCP-1
 
Table I.
 
Demographic and clinical features of tuberculosis 
cases and controls from Mexico
 
a
 
Parameter
Tuberculosis
(
 
n
 
 
 
 
 
 435)
Healthy
tuberculin
positive
(
 
n
 
 
 
 
 
 334)
Healthy
tuberculin
negative
(
 
n
 
 
 
 
 
 176)
 
Gender
Male, n (%) 296 (68) 230 (69) 122 (66)
Age (yr), mean 
 
 
 
 SD
Female 36   8 34   9 33   11
Male 37   5 38   3 37   6
BMIb (kg/m2),
mean   SD
Female 25.2   4.5 26.3   3.2 27.1   3.1
Male 24.8   5.1 25.5   4.2 26.5   2.6
Household income
(dollars/yr),
mean   SD
2,633   633 2,701   461 2,714   416
Smokers, n (%)c
Female 11 (8) 7 (7) 5 (9)
Male 59 (20) 53 (23) 39 (22)
Alcohol use, n (%)d
Female 7 (5) 6 (6) 2 (3)
Male 21 (7) 18 (8) 7(6)
aThe distribution of categorical variables was compared by  2 or Fisher’s exact tests, 
and that of continuous variables was done by one-way ANOVA. There were no 
significant differences between groups for any of the parameters.
bBMI was based on weight (self-reported before the development of disease in 
tuberculosis patients) and height (measured by a nurse).
cAll smokers reported consumption of  6 cigarettes per day.
dAll alcohol users reported consumption of  2 drinks per day.JEM VOL. 202, December 19, 2005 1651
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allele G has a dose effect. Indeed, the ORs for heterozy-
gous AG in tuberculosis cases versus tuberculin-positive and
-negative controls were 2.1 and 2.3, respectively, and in-
creased to 5.4 and 5.5, respectively, for the comparison of
homozygous GG (Table III).
Koreans have an admixture of two Asian populations
of Mongolian origin, with 55% Northern Asian and 45%
Southern Asian components (18). Thus, Koreans are much
more ethnically homogeneous than Mexican Mestizos, and
correction for population stratification/admixture was not
applied to this sample. In Korean control subjects, genotypes
of the MCP-1 gene were in Hardy-Weinberg equilibrium.
As in Mexicans, allele G of the MCP-1 gene was strongly as-
sociated with tuberculosis compared with healthy controls,
with a significant  2 of 32.28 (P   0.0001) and an OR of
2.63 (95% CI   1.85–3.73; Table IV). As in Mexicans, car-
riers of MCP-1 genotypes AG and GG were significantly
overrepresented among tuberculosis cases as compared with
healthy controls (Table V). A significant dose effect of the
MCP-1 allele G was also observed in Koreans, because
the OR for heterozygous AG in tuberculosis cases versus
healthy controls was 2.8 and strongly increased to 6.9 for the
comparison of homozygous GG (Table V).
Tuberculosis patients with the MCP-1 GG genotype have 
the highest MCP-1 and the lowest IL-12p40 
plasma concentrations
MCP-1 plasma levels were significantly higher in 145 tuber-
culosis patients from Mexico than in 102 controls (80 tuber-
culin reactors and 22 tuberculin-negative persons; 1,608  
662 pg/ml vs. 372   314 pg/ml; P   0.00001), which was
consistent with previous reports (19). Because the allele G in
the MCP-1 promoter increases gene expression (10, 20), we
examined plasma MCP-1 levels in patients with different
Table II. The allele G of the MCP-1 promoter region is associated with development of pulmonary tuberculosis (Mexican sample)a
Allele
TBb
(870 alleles)
PPD c
(668 alleles)
TB versus
PPD 
PPD d
(352 alleles)
TB versus
PPD 
n
(frequency)
n
(frequency)
n
(frequency)
NOS2A-954
C 824 (0.95) 627 (0.94) Not significant 329 (0.93) Not significant
G 46 (0.05) 41 (0.06) 23 (0.07)
MCP-1
–2518
A 244 (0.28) 325 (0.49) 172 (0.49)
G 626 (0.72) 343 (0.51)  2   12.9
P   0.0003
180 (0.51)  2   9.08
P   0.0026
RANTES-471
A 234 (0.27) 179 (0.27) Not significant 93 (0.26) Not significant 
G 636 (0.73) 489 (0.73) 259 (0.74)
MIP-1 -459
C 744 (0.86) 567 (0.85) Not significant 298 (0.87) Not significant
T 126 (0.14) 101 (0.15) 54 (0.13)
aMCP-1 alleles were typed by amplification fragment length polymorphism analysis. NOS2A, RANTES, and MIP-1  alleles were typed by amplification-created restriction site 
analysis, as detailed in Materials and methods. Groups were compared by  2 analysis.  2 values were corrected for population stratification and for the number of comparisons.
bTB   new cases of pulmonary tuberculosis.
cPPD    healthy tuberculin reactors.
dPPD    healthy tuberculin-negative persons.
Table III. The MCP-1 genotype GG is associated with development of pulmonary tuberculosis (Mexican sample)
MCP-1 genotypea
TBb
(n   435)
PPD c
(n   334) TB versus PPD 
PPD d
(n   176) TB versus PPD 
n (frequency) n (frequency) p-value OR (95% CI) n (frequency) p-value OR (95% CI)
AA 38 (0.09) 82 (0.25) 1 42 (0.24) 1
AG 168 (0.39) 161 (0.48) 0.0003 2.3 (1.5–3.5) 88 (0.50) 0.004 2.1 (1.3–3.5)
GG 229 (0.53) 91 (0.27) 0.00001 5.4 (3.4–8.6) 46 (0.26) 0.00001 5.5 (3.2–9.5)
aGroups were compared by  2 analysis Mantel-Haenszel statistics with genotypes arranged in an ordinal scale.
bTB   new cases of pulmonary tuberculosis.
cPPD    healthy tuberculin reactors.
dPPD    healthy tuberculin-negative persons.MCP-1 PROMOTER VARIANT AND TUBERCULOSIS SUSCEPTIBILITY | Flores-Villanueva et al. 1652
MCP-1 genotypes. Carriers of the GG genotype had the
highest MCP-1 levels (1,976   582 pg/ml), followed by
those with the AG (1,424   542 pg/ml) and AA (1,109  
546 pg/ml) genotypes, and these differences were statistically
significant (Fig. 1).
IL-12p40 plasma levels were significantly higher in tuber-
culosis patients from Mexico than in controls (1,270   507
pg/ml vs. 332   284 pg/ml; P   0.00001). When tubercu-
losis patients were stratified by MCP-1 genotypes, levels of
IL-12p40 were significantly lower in carriers of the GG gen-
otype (1,179   435 pg/ml) than in those with the AG (1,348
  525 pg/ml) or the AA (1,471   508 pg/ml) genotypes
(Fig. 2). There was a significant negative correlation between
MCP-1 and IL-12p40 levels in persons with the GG geno-
type (correlation coefficient    0.71; P   0.00001) but not
in those with the AA or AG genotypes. These findings sug-
gest that overproduction of MCP-1 in patients with the gen-
otype GG down-regulated IL-12p40 expression.
MCP-1 inhibits M. tuberculosis–stimulated IL-12p40 
production by monocytes
Monocytes are the major sources of MCP-1 and IL-12p40.
Because the plasma levels of these two molecules were nega-
tively correlated, we next evaluated production of these cy-
tokines by monocytes from persons with homozygous GG
and AA. We used cells from these because carriers of those
genotypes had the highest and lowest plasma levels of MCP-1,
respectively, and they represent the extreme phenotypes.
Monocytes were stimulated with 5  g/ml of a sonicate of M.
tuberculosis H37Rv, because preliminary experiments showed
that this concentration induced the highest concentrations of
IL-12p40 at 12–72 h of stimulation (unpublished data). Levels
of MCP-1 and IL-12p40 in culture supernatants increased
with time and were maximal at 48–72 h. MCP-1 levels were
significantly higher in homozygous GG than in homozygous
AA, whereas the reverse was true for IL-12p40 levels (Fig. 3).
There was a significant negative correlation between levels of
MCP-1 and IL-12p40 in supernatants from cells of homozy-
gous GG at 12, 24, and 48 h, with correlation coefficients
ranging from  0.53 to  0.60 and p-values of 0.01–0.02.
Addition of saturating amounts of anti–MCP-1 antibod-
ies to M. tuberculosis–stimulated monocytes from homozy-
gous GG significantly increased IL-12p40 levels (5,911  
964 pg/ml) compared with monocytes treated with no anti-
body (3,001   1037 pg/ml) and those treated with isotype
control antibodies (3,042   958 pg/ml; Fig. 4). In contrast,
Table V. The MCP-1 genotype GG is associated with 
development of pulmonary tuberculosis (Korean sample)
MCP-1
genotypea
TBb
(n   129)
Healthy 
controls
(n   162) TB versus healthy controls
n
(frequency)
n
(frequency) p-value OR (95% CI)
AA 20 (0.155) 66 (0.407) 1
AG 63 (0.488) 74 (0.457) 0.00063 2.8 (1.5–5.1)
GG 46 (0.357) 22 (0.136) 3.2   10 8 6.9 (3.4–14.1)
aGroups were compared by  2 analysis Mantel-Haenszel statistics with genotypes 
arranged in an ordinal scale.
bTB   new cases of pulmonary tuberculosis.
Figure 1. Tuberculosis patients with the MCP-1 GG genotype have 
the highest plasma concentrations of MCP-1. Plasma MCP-1 levels 
were measured by ELISA in 145 tuberculosis patients, 80 healthy tuberculin 
reactors, and 20 healthy tuberculin-negative controls. There were no differ-
ences in MCP-1 levels between the healthy tuberculin reactors and tuberculin-
negative persons, so they were combined into a single group (controls). 
MCP-1 values are shown as medians (horizontal lines), the 25th and 75th 
percentiles (boxes), and ranges (whiskers). (A) Distribution of plasma 
MCP-1 values for tuberculosis patients and controls. (B) MCP-1 levels 
in tuberculosis patients, stratified by MCP-1 genotype. (C) A summary 
with values of MCP-1 means and standard deviations is shown. p-values 
are based on the Bonferroni least significant difference test.
Table IV. The allele G of the MCP-1 promoter region is 
associated with development of pulmonary tuberculosis 
(Korean sample)a
Allele
TBb
(258 alleles)
Healthy controls
(324 alleles)
TB versus
healthy controls
MCP-1
–2518
A 103 (0.40) 206 (0.64)
G 155 (0.60) 118 (0.36)  2   32.28
p   0.00001
aMCP-1 alleles were typed by amplification fragment length polymorphism analysis. 
NOS2A, RANTES, and MIP-1  alleles were typed by amplification-created restriction site 
analysis, as detailed in the methods. Groups were compared by chi-square analysis.
bTB   new cases of pulmonary tuberculosis.JEM VOL. 202, December 19, 2005 1653
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anti–MCP-1 did not further increase IL-12p40 production
in cells from homozygous AA.
To determine whether addition of exogenous MCP-1
would affect M. tuberculosis–stimulated production of IL-
12p40, we used cells from MCP-1 homozygous AA because
they produced high levels of IL-12p40 and relatively low
levels of MCP-1 that may not be sufficient to inhibit IL-
12p40 production. When we cultured monocytes from these
individuals with exogenous MCP-1 before stimulation with
M. tuberculosis, 2,000 and 4,000 pg/ml reduced MCP-1 con-
centrations by 24 and 36%, respectively (Fig. 5).
DISCUSSION
We found that the allele G of the MCP-1 promoter–enhanc-
ing region is strongly associated with increased odds of
developing active pulmonary tuberculosis after infection in
Mexicans and Koreans. Persons with the MCP-1 genotypes
AG and GG were 2.3- and 5.4-fold and 2.8- and 6.9-fold
more likely to develop tuberculosis than those with the AA
genotype in Mexicans and Koreans, respectively. In addi-
tion, tuberculosis patients from Mexico carrying the geno-
type GG had the highest plasma levels of MCP-1 and the
lowest plasma levels of IL-12p40, and these values were neg-
atively correlated. Furthermore, stimulation of monocytes
from normal persons bearing the GG genotype with M. tu-
berculosis antigens yielded higher concentrations of MCP-1
and lower concentrations of IL-12p40 than parallel experi-
ments with monocytes from persons of the AA genotype.
Addition of anti–MCP-1 increased IL-12p40 levels in M.
tuberculosis–stimulated monocytes from persons of the GG
genotype, and addition of exogenous MCP-1 reduced IL-
12p40 production by M. tuberculosis–stimulated monocytes
from persons of the AA genotype. The sum of these findings
suggests that persons bearing the MCP-1 genotype GG are at
increased risk for progression of tuberculosis infection to ac-
tive disease, which is caused by reduced production of IL-
12p40 and a depressed Th1 response.
Compared with previous studies (22, 28–34) evaluating
genetic factors associated with susceptibility to tuberculosis,
this study was distinctive. First, to maximize the likelihood of
detecting effects of genetic factors controlling progression to
active disease after recent exposure, we selected sputum
smear–positive tuberculosis patients with culture-confirmed
disease and excluded those with chronic illnesses, including
malnutrition, which may predispose to tuberculosis. Second,
we selected new tuberculosis cases and excluded those with
Figure 2. Tuberculosis patients with the MCP-1 GG genotype have 
the lowest plasma concentrations of IL-12p40. Plasma IL-12p40 levels 
were measured by ELISA in 145 tuberculosis patients, 80 healthy tuberculin 
reactors, and 20 healthy tuberculin-negative controls. There were no 
differences in IL-12p40 levels between the tuberculin reactors and 
tuberculin-negative persons, so they were combined into a single group 
(controls). IL-12p40 values are shown as medians (horizontal lines), the 
25th and 75th percentiles (boxes), and ranges (whiskers). (A) Distribution 
of plasma IL-12p40 levels. (B) IL-12p40 levels in tuberculosis patients, 
stratified by MCP-1 genotype. (C) A summary with values of IL-12p40 
means and standard deviations is shown. p-values are based on the 
Bonferroni least significant difference test.
Figure 3. MCP-1 and IL-12p40 concentrations in M. tuberculosis–
stimulated monocytes. Monocytes from 20 persons with the AA geno-
type and 20 persons with the GG genotype were cultured in medium alone 
or with 5  g/ml of M. tuberculosis sonicate, as outlined in Materials and 
methods. Supernatants were harvested at the time points indicated, and 
MCP-1 and IL-12p40 concentrations were measured by ELISA. Mean values 
and standard deviations are shown for cytokine levels in M. tuberculosis–
stimulated monocytes. MCP-1 and IL-12p40 were not detected in super-
natants of cells cultured in medium alone. In persons with the GG geno-
type, MCP-1 and IL-12p40 concentrations were negatively correlated 
at 12 h (correlation coefficient    0.55; P   0.01), 24 h (correlation 
coefficient    0.60; P   0.01), and 48 h (correlation coefficient    0.53; 
P   0.02). MCP-1 and IL-12p40 levels were not correlated in persons with 
the AA genotype.MCP-1 PROMOTER VARIANT AND TUBERCULOSIS SUSCEPTIBILITY | Flores-Villanueva et al. 1654
previous episodes of tuberculosis. Third, we chose patients
with clinical and epidemiological features that were strongly
suggestive of active tuberculosis of short evolution after re-
cent exposure. In the Mexican sample, we selected as con-
trols healthy tuberculin reactors who were not vaccinated
with Bacillus Calmette-Guerin (BCG) and had been in re-
cent contact with a tuberculosis case, so we were confident
that they were infected with M. tuberculosis. We compared al-
lele and genotype frequencies in tuberculosis patients with
those in healthy tuberculin reactors and healthy tuberculin-
negative persons, allowing us to distinguish susceptibility to
progression of infection to disease from susceptibility to tu-
berculosis infection. In addition, subjects were followed for 3
yr to ensure that they did not develop tuberculosis and,
therefore, had protective natural immunity. The MCP-1 al-
lele G was more commonly found in tuberculosis patients
compared with healthy tuberculin reactors, demonstrating
that this allele increases the likelihood of progression of tu-
berculosis infection to disease. In contrast, the MCP-1 allele
G was equally common in healthy tuberculin reactors and
healthy tuberculin-negative persons, indicating that this allele
does not increase susceptibility to infection. In summary, by
selecting persons with clear phenotypes and by minimizing
the effects of nongenetic risk factors, our results provide
strong evidence that the MCP-1 allele G and genotype GG
are associated with increased risk of progression from tuber-
culosis infection to active disease in Mexicans. This strategy
has allowed us to identify a gene influencing expression of
disease in other populations. Indeed, we could replicate these
findings in Korean tuberculosis cases and healthy controls.
Our results contrast with those of Jamieson et al., who
found no association of the MCP-1 –2518 allele G with sus-
ceptibility to tuberculosis in a study of cases and pseudocon-
trols derived from 92 families in Brazil (3). Our study may
have yielded positive results because large case-control studies
of unrelated persons have an inherently higher power to de-
tect genes controlling the expression of complex traits than
Figure 4. Neutralization of MCP-1 increases IL-12p40 production 
by M. tuberculosis–stimulated monocytes from persons with the 
MCP-1 GG genotype. Monocytes from 20 persons with the genotype AA 
and 20 persons with the genotype GG were cultured with 100  g/ml anti–
MCP-1, 100  g/ml of isotype control antibodies, or no antibodies for 1 h, 
then stimulated with 5  g/ml M. tuberculosis sonicate, as outlined in 
Materials and methods. Supernatants were harvested at 24 h, and IL-12p40 
concentrations were determined by ELISA. Mean values and standard devi-
ations are shown. IL-12p40 levels in the three groups differed significantly 
only in persons with the GG genotype by one-way ANOVA (P   0.0001). 
For persons with the GG genotype, values for cells treated with anti–MCP-1 
were significantly higher than those of the other two groups (P   0.0001 
using the Bonferroni least significant difference test).
Figure 5. MCP-1 inhibits IL-12p40 production by M. tuberculosis–
stimulated monocytes. Monocytes from five persons with the AA geno-
type were cultured with 5  g/ml M. tuberculosis sonicate and treated with 
medium alone or with different concentrations of recombinant human 
MCP-1, as outlined in Materials and methods. Supernatants were harvested 
after 24 h, and IL-12p40 was measured by ELISA. Mean values and standard 
deviations are shown. p-values were corrected for multiple comparisons, 
and only significant values are shown. IL-12p40 was not detected in 
supernatants of monocytes treated with medium alone, with or without 
recombinant MCP-1.JEM VOL. 202, December 19, 2005 1655
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small, family-based studies (21). Discrepant results may have
also arisen from differences in the study design. We have
conducted case-control studies of unrelated individuals in
which genotype and exposure or genotypes at unlinked loci
occur independently, whereas Jamieson et al. used cases and
pseudocontrols derived from nuclear families (3), a design
where those critical features are lost (21). This severely de-
creases the power to detect genes involved in the expression
of complex multifactorial diseases because adjustment for cor-
relations and analytical methods that rely on conditional
probabilities are required for the analysis of case-pseudocon-
trol studies (21). Alternatively, differences in the characteris-
tics of the populations studied may explain our discrepancies.
Genomic screening studies have identified several markers
linked to tuberculosis susceptibility that differ from popula-
tion to population (22, 23). Population-dependent variations
in the frequency of susceptibility alleles and in the strength of
linkage disequilibrium between markers and differences in
environmental conditions and lifestyles may explain these ap-
parently discrepant results (24–27). Likewise, in candidate
gene studies, the natural resistance–associated macrophage protein
1, vitamin D receptor, IL-10 genes, and the IL-1 cluster of
genes have been associated with susceptibility to tuberculosis
in some ethnicities but not in others (28–34), supporting the
notion that the influence of individual genes may vary in
populations that differ in susceptibility allele frequencies or
the composition of other susceptibility genes or in environ-
mental factors that alone or in interaction induce the expres-
sion of disease susceptibility (24–27). Future studies with suf-
ficient power may identify MCP-1 as a gene with important
main or interactive contributions in susceptibility to develop-
ing tuberculosis. We anticipate that our results will have a
substantial impact in the field because of the very high fre-
quency of the predisposing MCP-1 allele G and the consider-
ably increased odds of developing disease in carriers of this al-
lele in two populations with different ethnicities.
Our data suggest that very high levels of MCP-1 inhibit
IL-12p40 production in carriers of the MCP-1 genotype GG,
perhaps adversely affecting the immune response to M. tubercu-
losis infection. Indeed, only in tuberculosis cases and in cultures
of cells from carriers of the MCP-1 genotype GG did we ob-
serve that IL-12p40 levels were negatively correlated with cor-
responding MCP-1 concentrations. Our findings suggest that
IL-12p40 may be down-regulated by MCP-1 concentrations
only when they are above a certain threshold. Only saturating
amounts of anti–MCP-1–neutralizing antibodies restored IL-
12p40 production by M. tuberculosis–stimulated monocytes
from individuals of the GG genotype, and only the addition of
very high concentrations of MCP-1, equivalent to those in
plasma of tuberculosis cases carrying the genotype GG, inhib-
ited M. tuberculosis–induced IL-12p40 production by mono-
cytes from individuals of the AA genotype (Fig. 5). Our in
vitro observations are consistent with previous in vitro studies
in human monocytes (35) and murine dendritic cells, demon-
strating that MCP-1 inhibits IL-12 production (36, 37). More-
over, only those transgenic mice producing very high levels of
MCP-1 had increased susceptibility to disease from intracellular
pathogens, including M. tuberculosis (38).
The IL-12/IL-23/IFN-  axis plays a pivotal role in resis-
tance to intracellular pathogens, including M. tuberculosis
(39–46). IL-12p40 is a component of IL-12 and IL-23 and is
required for their binding to the IL-12 receptor  1 subunit
(47). Thus, inhibition of IL-12p40 by MCP-1 in MCP-1
homozygous GG could contribute to development of tuber-
culosis. In agreement with this concept, individuals carrying
mutations in the IL-12p40 and IL-12 receptor  1 genes have
increased susceptibility to mycobacterial infection (48–50).
In summary, we found that the MCP-1 –2518 G allele
has a dose effect on the likelihood of progression of tubercu-
losis infection to disease in Mexicans and Koreans, and that
Mexicans and Koreans with the GG genotype were 5.4- and
6.9-fold more likely, respectively, to develop tuberculosis
than those with the AA genotype. Correlation of MCP-1
and IL-12p40 plasma levels in Mexicans, as well as in vitro
experiments with MCP-1 and IL-12p40, suggests that per-
sons with the genotype GG produce very high concentra-
tions of MCP-1, which inhibits production of IL-12p40 and
increases the odds that M. tuberculosis infection will progress
to disease.
MATERIALS AND METHODS
Sample size calculation
Preliminary data from 40 tuberculosis cases and 40 controls from Mexico
showed that the frequencies of the MCP-1 allele G were 0.75 and 0.45, re-
spectively, in tuberculosis cases and controls. Based on these data, we calcu-
lated that a sample size of 251 tuberculosis cases and 251 controls would pro-
vide 90% power to detect an OR of 2 with a two-sided   of 0.01. To ensure
adequate power after correction for population stratification and multiple
comparisons, we enrolled 445 tuberculosis patients and 518 controls.
Subjects
We conducted unmatched case-control studies in Mexico and Korea.
Mexican sample. Tuberculosis patients and controls were Mexican adults
of Mestizo ethnicity (18–50 yr old) recruited in Mexico D.F. as part of the
World Health Organization’s DOTS community surveillance program for
early detection of new tuberculosis cases (13). All subjects had negative se-
rologic tests for HIV infection, were of similar socioeconomic statuses, and
were unrelated to the third generation, as determined by a questionnaire.
Persons with a prior history of tuberculosis, cancer, organ transplantation,
primary immunodeficiency, therapy with immunosuppressive drugs such as
corticosteroids, asthma, autoimmune or endocrine disorders, or chronic
cardiopulmonary, hepatic or renal disease were excluded. The BMI for each
subject was determined, based on self-reported weight, before disease in the
case of tuberculosis patients, and height was measured by a nurse. Persons
with a BMI  18.5 kg/m2 were considered to be malnourished (51–53) and
were excluded.
From April 1999 through July 2004, 445 tuberculosis cases and 518
healthy controls were enrolled in the study. 20 tuberculosis patients (4%)
and 25 controls (5%) declined to participate in the study. All subjects pro-
vided informed consent under protocols approved by the institutional re-
view boards of the Dana-Farber Cancer Institute and Mexican Instituto Na-
cional de Ciencias Medicas y Nutricion “Salvador Zubiran.”
Tuberculosis cases had symptoms (weight loss  10 kg, cough, fever,
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radiographic findings consistent with recent pulmonary tuberculosis, a posi-
tive sputum acid-fast smear and culture confirmed for M. tuberculosis, and a
history of substantial exposure to tuberculosis in the preceding 8 mo. Pa-
tients with predominant upper lobe infiltrates, cavitary disease, military tu-
berculosis, or parenquimal or pleural fibrosis on chest radiographs were ex-
cluded to increase the chances of recruiting new cases of tuberculosis (54,
55). Patients with pleural effusions on chest radiographs were also excluded
to avoid misclassification, because tuberculosis pleuritis could also be a man-
ifestation of remote infection (56).
Controls were healthy adults who had recent contact with a tuberculo-
sis patient, and most were neighbors or co-workers of the tuberculosis cases.
A tuberculin skin test was administered to all controls, using the Mantoux
method to deliver 5 tuberculin U of purified protein derivative RT/23
(Statens Serum Institut) intradermally (57). The diameter of induration was
measured 48 h after inoculation. Tuberculin-negative persons were retested
1 wk later to confirm the result. Controls were stratified into tuberculin-
positive and -negative groups. All tuberculin reactor controls had tuberculin
reactions of  10 mm, have had at least three negative sputum smears for
acid-fast bacilli, and normal chest radiographs. They were followed for at
least 3 yr and did not develop tuberculosis. None of these individuals re-
ceived isoniazid, consistent with standard medical practice in Mexico. We
carefully selected tuberculin reactor controls that were not vaccinated with
M. bovis BCG as they had no scars suggestive of BCG vaccination (58) and
denied a history of having BCG vaccination. Tuberculin-negative controls
had two consecutive tuberculin tests that showed  5 mm of induration.
Controls whose tuberculin skin tests showed 5–10 mm of induration were
excluded from the study.
Korean sample. Tuberculosis patients and controls were Korean adults
(17–78 yr old) recruited from Chungnam National University Hospital, Kon-
yang University Hospital, and Bok-syp-ja Clinic, all of which are located in
Daejeon, South Korea. Unrelated, healthy blood donors were recruited as
controls. Patients with tuberculosis were included after the diagnosis was
made by medical, biochemical, and radiological assessment, microscopic ex-
amination of sputum smear using Ziehl-Neelsen staining, and culture of M.
tuberculosis from sputum. All subjects had negative serologic tests for HIV in-
fection and had no serious illnesses other than tuberculosis. DNA samples
from 129 tuberculosis cases and 162 healthy controls were used for SNP anal-
ysis. The study was approved by the Bioethics Committee of Chungnam
University Hospital’s review board overseeing studies on samples from human
subjects, and all participants gave written consent.
Blood samples
Blood samples ( 1 ml) were stored at  20 C, thawed in batches of 50, and
centrifuged to obtain cellular pellets. Genomic DNA was isolated from
these pellets with DNA extraction kits (QIAGEN). Some aliquots of plasma
( 0.5 ml) were also stored at  20 C and used for ELISA tests. Blood sam-
ples from Koreans were provided by S.-S. Jung, J.-W. Son, and Y.-J. Lim
(Chungnam National University Hospital, Daejeon, South Korea).
SNP analysis
Many SNPs are present in the MCP-1, NOS2A, RANTES, and MIP-1 
genes. We studied SNPs that alter expression of the gene or were associated
with disease (10–12). These SNPs were genotyped in duplicate discrepancies
solved by sequencing. There were no discrepancies in typing results of MCP-1.
We observed discrepant data in  5% of the cases for the RANTES SNP,
which were resolved by sequencing. The region containing the –2518 G to A
transition in the MCP-1 promoter region (10) was amplified from 100 ng
of genomic DNA using the forward primer (5 -GCTCCGGGCCCAG-
TATCT-3 ) and reverse primer (5 -ACAGGGAAGGTGAAGGGTATGA-
3 ) and a Hot Start PCR (Applied Biosystems). Restriction fragment length
after PCR was used for the detection of MCP-1 alleles. The allele G creates a
PvuII restriction site yielding two fragments of 182 and 54 bp, respectively.
The allele A was identified by the presence of a 236-bp undigested fragment.
To confirm our results in MCP-1 gene analysis, we sequenced 50 randomly
selected cases and controls, respectively. The SNPs in the NOS2A G  954 C
(11), RANTES G –471 A, and MIP-1  C 459 T (12) transitions were
typed by amplification-created restriction sites, as previously described.
Studies of MCP-1 and IL-12p40
Plasma was obtained from a convenience sample of 145 tuberculosis cases,
80 tuberculin reactors, and 22 tuberculin-negative controls from Mexico.
These samples were obtained before initiating therapy. MCP-1 and IL-12
p40 levels were measured by ELISA (BD Biosciences).
Buffy coats or leukopacks were obtained at the Dana-Farber Cancer In-
stitute blood bank from healthy donors (20 MCP-1 homozygous GG and 25
homozygous AA). PBMCs were obtained by Ficoll-gradient centrifugation.
106 PBMCs were used to isolate genomic DNA. The remaining PBMCs
were frozen in FCS and 5% DMSO in liquid nitrogen until used. Monocyte-
enriched preparations were obtained from PBMC by NycoPrep (Axis-Shield)
gradient centrifugation. These contained 75–90% monocytes, as assessed by
flow cytometry with anti-CD14– and Giemsa-stained cytocentrifuge prepara-
tions. Based on these percentages, the number of monocytes included in the
experiments outlined in the next two paragraphs was calculated.
In some experiments, 7   106 monocytes/ml were cultured in tripli-
cate in 48-well plates in a final volume of 0.5 ml of complete RPMI 1640,
with or without 5  g/ml M. tuberculosis H37Rv sonicate for 72 h. Superna-
tants were collected at time points ranging from 12–72 h, and IL-12p40 and
MCP-1 levels were measured in supernatants by ELISA.
In experiments involving the addition of antibodies or recombinant hu-
man MCP-1 (R&D Systems), monocytes were cultured at 7   106 cells/ml
in complete RPMI 1640 with 10% FCS in petriPERM hydrophobic Petri
dishes (Vivascience AG) for 1 h, with or without different concentrations of
recombinant human MCP-1, anti–MCP-1–neutralizing antibodies, or iso-
type control antibodies (both from BD Biosciences). Cells were then washed
three times with RPMI 1640, resuspended, and plated in 48-well plates at
7   106 cells/ml in 0.5 ml of complete RPMI 1640 and 10% FCS with 5  g/
ml H37Rv sonicate, with or without recombinant human MCP-1, anti–
MCP-1, or isotype control antibodies, for 24 h. Supernatants were collected
and stored at  20 C until IL-12p40 concentrations were measured.
Statistical analyses
Statistical analysis was done with Intercooled STATA9 software (Stata Cor-
poration). Hardy-Weinberg equilibrium was calculated using  2 tests for
n(n   1)/2 degrees of freedom, where n is the number of alleles in the
polymorphism tested (59). Expected genotype proportions were obtained
using allele frequencies observed in the controls and the binomial equation.
Associations of alleles with disease were analyzed using 2   2 contin-
gency tables, two-sided  2, or Fisher’s exact tests, as appropriate (60). For
the analysis of allele associations with disease in the Mexican sample,  2 val-
ues were corrected for population stratification, primarily to control for dif-
ferences in levels of admixture between cases and controls, by dividing these
 2 values by an estimated value of   (15).   was calculated as the mean of  2
values from comparison of the allele frequencies of 30 SNPs located across
the genome (15, 16) that were not in linkage disequilibrium (Table S1).
The resulting  2 values were further adjusted according to the number of
comparisons using the Bonferroni correction.
We used multiple 2   2 tables, with genotypes arranged in an ordinal
scale, and  2 Mantel-Haenszel statistics to test for genotype association with dis-
ease. To test for additive effects we used the score test for trend of the ORs.
Differences in MCP-1 and IL-12p40 levels in plasma between cases
and controls and in some in vitro studies were determined using unpaired
Student’s t tests (with the Bonferroni correction) as appropriate. One-way
analysis of variance (ANOVA), followed by the Bonferroni least significant
difference test for multiple comparisons, was used to analyze plasma cyto-
kine levels and to examine in vitro IL-12p40 levels in samples treated with
anti–MCP-1 antibodies. Pearson’s and Spearman’s tests were used to evalu-
ate correlations. To examine mean cytokine levels in culture supernatants
over time in homozygous GG versus AA, we used two-group repeated
measures ANOVA with subjects nested in groups. Before running ANO-JEM VOL. 202, December 19, 2005 1657
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VAs we confirmed that normality (normal distribution of the data) and ho-
mocedasticity (the variances were homogeneous) assumptions were not vio-
lated, using Shapiro-Wilk and Bartlett’s tests, respectively.
Online supplemental material
Table S1 lists the SNP typed as genomic controls, frequency of alleles at
each loci, and  2 values resulting from comparisons of allele frequencies in
Mexican cases and controls. At the end of the table the value  , calculated as
outlined in Statistical analyses, is presented. Table S2 shows the demo-
graphic and clinical features of Korean cases and controls. Online supple-
mental material is available at http://www.jem.org/cgi/content/full/jem.
20050126/DC1.
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